Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oblimersen + Interferon Alfa in Metastatic Renal Cancer
NCT00059813Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2003
- Primary completion
- Jun 2005
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oblimersen in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 5 years. Started Aug 2003; status: completed.
02
Drugs
oblimersen
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00059813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00059813.